On the stock market since 1994, it operates in the world of health and science. It has 20,700 employees. Now — the numbers.
This is an established company with proven profits.
The biggest line carries real weight, but it doesn’t decide everything on its own.
Average growth of 5% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $19.9B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 82% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 9% a year on average.
Over the last 12 months, company executives reported 26 buys and 17 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $9.83 — 85% above today’s price.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 3/10.
On our five-subject report card, BHC sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: BHC is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.